Article Type
Original Study
Abstract
Background: Mycosis fungoides(MF) is considered as the most prevalentform of cutaneous T-cell lymphoma. It is well known that diagnosis of MF isdifficult due to its extremely diverse manifestations and non-specific histopathologicalfindings. Besides, MF has a chronic relapsing course, and afflictedpatients are often receiving multiple as well as consecutive drug regimens. Objective:Toassess the demographic profiles, skin-directed therapies, systemictherapies, and the response to therapy in patients with MF.Methods:This retrospective study was performed on cases with pathologicalconfirmation of MF. Patients' data were collected from Clinical OncologyandDermatology departments, Mansoura University Hospital from January2006to December 2013. Results:A total of 55 cases(30 males and 25 females) with mean age of45.07years at time of diagnosis were reviewed. The majority (89%) of patientshad an early-stage (I and II) MF. Forty-four (80%) patients had classicMF;7 (12.7%) hypo-pigmented MF; and 4 (7.3%) other variants. Initial diagnosisof other skin diseases was 41.8%. Phototherapy was the commonestlineof therapy used for those patients. At the final assessment, 7 (12.7%)patientshad complete response; whereas 48 (87.3%) had partial response.Conclusion:MF might clinically and histopathologically simulates benignskindiseases mainly in early stages. Precise clinico-pathological correlationisnecessary to support the diagnosis. Treatment of MF is principally determinedby the disease extension and its effect on quality of life, as well aspatient´sage and other comorbid conditions. Skin-directed therapies appliedin early-stage MF can give prolonged remissions, although diseasecureis unclear.
Recommended Citation
Alashry, Shereen; Aboelnaga, Engy; and Elbeshbeshi, Wafaa
(2017)
"Clinical Manifestations and Outcomes of Patients with Mycosis Fungoides in Mansoura, Egypt,"
Mansoura Medical Journal: Vol. 47
:
Iss.
2
, Article 1.
Available at:
https://doi.org/10.21608/mjmu.2017.124941
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.